Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03632135 · ClinicalTrials.gov registry record · Phase 3
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
A Phase 3 study, sponsored by Cordgenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT03632135: Completed Phase 3 study, sponsored by Cordgenics.
NCT03632135 is a Phase 3 study that has completed, run by Cordgenics. The registered enrollment target is 78 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03632135, a Phase 3 study, has completed, sponsored by Cordgenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent glioblastoma (GBM).
Primary Outcome
Overall survival (OS) in recurrent GBM patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician.
Interventions
- DRUG Chemotherapy
- DIAGNOSTIC_TEST ChemoID assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2018-05-20 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 3 |
What the finished NCT03632135 record still lists
NCT03632135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT03632135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03632135 about?
NCT03632135 is a clinical study titled "Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma". The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent glioblastoma (GBM).
What is the current status of trial NCT03632135?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2018-05-20. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03632135?
The interventions under investigation include: Chemotherapy (DRUG), ChemoID assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03632135?
This trial is sponsored by Cordgenics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03632135's enrollment target sits among peer trials
78 1769th of 2000 higher than 230 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI